About this event:

Date: September 9, 2025

Time: 11 am EDT | 8 am PDT |

5 pm CEST

Duration: 60 minutes

Typically, scientists use CHO cells to produce antibody-based therapeutics and recombinant proteins. However, some proteins are difficult to express in CHO cells, resulting in low titer levels, truncation issues, or undesired non-human post translational modifications.

WuXi Biologics is launching WuXia293^Stable—a technology platform for stable human embryonic kidney 293—specially designed for the development and manufacturing of difficult-to-express molecules. This novel platform for cell line development demonstrates high titer, robust stability, and superior quality. It significantly enhances developability and manufacturability, offering a highly efficient CMC solution for biologics sophisticated in both structure and function.

In this webinar, WuXi Biologics introduces a stable HEK293 cell line, highlighting how the WuXia293^Stable cell line:

• Eliminates or significantly alleviates truncation issues in expressing complex molecules while maintaining high titers.
• Achieves a fed-batch titer of up to five g/L for monoclonal antibodies, while significantly improving purity.
• Maintains stable expression and consistent quality during long-term cell passages, enabling scalable clinical and commercial manufacturing. Fed-batch operates at a 2,000 L scale. For perfusion, the scale is 1,000 L scale.

Additionally, WuXi Biologics provides proprietary HEK293 cells, BSL-2 facilities, full-spectrum cell bank testing, and viral clearance studies. Together, these capabilities deliver a single-source CMC solution.